Treatment with MX-IV ameliorated ICV-STZ-provoked oxidative stress and neuro-inflammation-associated hazards, namely Aβ deposition, tau hyperphosphorylation, neuronal death, and cognitive impairment. Here, MAPT is linked to Cognitive impairment.